Payment overview · 2025
General Payments
$714.33
23 reported records · 9 companies
Healthcare provider profile · identity verified
Nidal B Radwan, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH MIAMI BEACH, FL · NPI 1902856875
Verified facts
What the public records show
CMS Open Payments records show Nidal B Radwan, MD received $714.33 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $343.66 | 48.1% | 8 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $116.50 | 16.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.67 | 7.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.56 | 7.6% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $42.32 | 5.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.56 | 5.7% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$26.56 | 3.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.05 | 2.5% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $15.45 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.33 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $145.51 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $81.55 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.17 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.67 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.67 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $42.32 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $34.95 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 331 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 77 |
| Lisinopril | Lisinopril | 222 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 50 |
| Eliquis | Apixaban | 166 | 35 |
| Furosemide | Furosemide | 157 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 47 |
| Xarelto | Rivaroxaban | 154 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 37 |
| Famotidine | Famotidine | 140 | 30 |
| Nifedipine Er | Nifedipine | 140 | 45 |
| Gabapentin | Gabapentin | 135 | 41 |
| Metformin Hcl | Metformin Hcl | 129 | 45 |
| Levetiracetam | Levetiracetam | 124 | 23 |
| Baclofen | Baclofen | 115 | 16 |
| Losartan Potassium | Losartan Potassium | 112 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 34 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 104 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 33 |
| Simvastatin | Simvastatin | 98 | 37 |
| Carvedilol | Carvedilol | 89 | 30 |
| Mirtazapine | Mirtazapine | 88 | 17 |
| Alprazolam | Alprazolam | 85 | suppressed |
| Omeprazole | Omeprazole | 80 | 25 |
| Donepezil Hcl | Donepezil Hcl | 79 | 18 |
| Lactulose | Lactulose | 73 | 11 |
| Trazodone Hcl | Trazodone Hcl | 73 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 31 |
| Potassium Chloride | Potassium Chloride | 65 | 12 |
| Memantine Hcl | Memantine Hcl | 64 | 14 |
| Sertraline Hcl | Sertraline Hcl | 64 | 15 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 59 | 25 |
| Latanoprost | Latanoprost | 56 | 17 |
| Prednisone | Prednisone | 54 | 17 |
| Megestrol Acetate | Megestrol Acetate | 53 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 18 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | 16 |
| Clonidine Hcl | Clonidine Hcl | 35 | 16 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | 14 |
| Linzess | Linaclotide | 32 | suppressed |
| Tivicay | Dolutegravir Sodium | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 23 |
| Glipizide | Glipizide | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Clarithromycin | Clarithromycin | 27 | 19 |
| Labetalol Hcl | Labetalol Hcl | 27 | 12 |
| Spironolactone | Spironolactone | 27 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 14 |
| Novolog Flexpen | Insulin Aspart | 25 | 11 |
| Temazepam | Temazepam | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Valsartan | Valsartan | 22 | 12 |
| Atenolol | Atenolol | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Edurant | Rilpivirine Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | 14 |
| Haloperidol | Haloperidol | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | 11 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Matzim La | Diltiazem Hcl | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 12 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.33 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, COLLAGENASE SANTYL, DOVATO, Exablate, FARXIGA, FREESTYLE LIBRE, KRYSTEXXA, LOKELMA, MOUNJARO, Ozempic, Rybelsus, VALTOCO, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error